Answers are grounded in this paper and cite their sources.
Background and Aims: Glycoprotein B (gB) is among the most important immunogenic proteins of HSV-1 that is now being used as recombinant vaccine to induce protectively against the virus. It is believed that gB is responsible for induction of neutralizing antibody and up to 90% of CTL (Cytotoxic T Cell) activity against HSV-1 in some haplotypes. Methods: In the present study the antibody titer induced by a gB based DNA vaccine and the protective effect of the candidate vaccine in BALB/c mice in comparison with those induced by the whole virus were evaluated. DNA plasmid carrying full-length of gB-1 was constructed and its ability to express the protein was confirmed by immunofluorescence test. Results: Humoral immune response and protective effect of the constructed vector were evaluated in BALB/c mice. Conclusion: The neutralizing antibody titer induced by the DNA vaccine was significantly lower than the one induced by the whole virus, although, both of vaccines could confer 100% protectively against HSV-1 challenge.
No takes yet. Share an insight, caveat, or question.
Bamdad et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: